Illumina, a prominent life sciences company, finds itself on the clock as it must divest Grail, a cancer test maker, within 12 months, according to a directive from the European Commission. This directive comes as a result of Illumina’s premature acquisition of Grail, pending the outcome of its legal battle.
The European Commission’s order stipulates that if Illumina fails to win its legal challenge in court, the divestiture must proceed. However, there is a provision that could extend the timeframe by an additional three months. Illumina is also granted the flexibility to explore various options, including third-party sales or capital market transactions, as reported by Reuters.
Should Illumina choose the path of a capital markets transaction, it would be required to fund Grail based on the cancer test maker’s long-term plan, providing two and a half years’ worth of financial support. Furthermore, the order allows Illumina to retain up to a 14.5% stake in Grail and reinstate the previous royalty arrangement.
Read more: Illumina Heads To Court Over EU Order To Keep Grail Separate
The background to this situation lies in EU antitrust regulators’ decision to order Illumina to divest Grail after the $7.1 billion deal was completed without securing their approval. Concerns arose that Illumina might hinder Grail’s competitors from accessing its technology to develop blood-based early cancer detection tests.
Illumina has vehemently challenged the European Union’s jurisdiction over the acquisition of Grail, a dispute currently awaiting a resolution from the European Court of Justice (ECJ). Should Illumina succeed in this jurisdictional appeal or in a final decision from the U.S. Fifth Circuit Court of Appeals, the divestiture order will be revoked. However, if Illumina fails to secure victory in either of these legal battles, it will indeed divest Grail as mandated by the European Commission.
Source: Reuters
Featured News
EU Set to Fine Apple in First Major Enforcement of Digital Markets Act
Nov 5, 2024 by
CPI
Six Indicted in Federal Bid-Rigging Schemes Involving Government IT Contracts
Nov 5, 2024 by
CPI
Ireland Secures First €3 Billion Apple Tax Payment, Boosting Exchequer Funds
Nov 5, 2024 by
CPI
Italy’s Data Protection Authority Criticizes Intesa’s Handling of Customer Data
Nov 5, 2024 by
CPI
Italy Halts Sale of ITA Airways Stake to Lufthansa Amid Price Dispute
Nov 5, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Remedies Revisited
Oct 30, 2024 by
CPI
Fixing the Fix: Updating Policy on Merger Remedies
Oct 30, 2024 by
CPI
Methodology Matters: The 2017 FTC Remedies Study
Oct 30, 2024 by
CPI
U.S. v. AT&T: Five Lessons for Vertical Merger Enforcement
Oct 30, 2024 by
CPI
The Search for Antitrust Remedies in Tech Leads Beyond Antitrust
Oct 30, 2024 by
CPI